% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Cremer:278358,
      author       = {A. Cremer$^*$ and J. Enssle$^*$ and S. Pfaff and K. Kouidri
                      and F. Lang and C. Brandts$^*$ and A. Zeiher and S. Cremer
                      and B. Steffen$^*$ and H. Serve$^*$ and G. Bug},
      title        = {{T}reatment with midostaurin and other {FLT}3 targeting
                      inhibitors is associated with an increased risk of
                      cardiovascular adverse events in patients who underwent
                      allogeneic hematopoietic stem cell transplantation with
                      {FLT}3-mutated {AML}.},
      journal      = {Annals of hematology},
      volume       = {102},
      number       = {10},
      issn         = {0006-5242},
      address      = {New York},
      publisher    = {Springer},
      reportid     = {DKFZ-2023-01612},
      pages        = {2903-2908},
      year         = {2023},
      note         = {2023 Oct;102(10):2903-2908},
      abstract     = {The addition of midostaurin to standard chemotherapy has
                      improved survival in patients with FLT3-mutated AML.
                      However, the impact of midostaurin and other FLT3 inhibitors
                      (FLT3i) on cardiovascular adverse events (CAEs) has not been
                      studied in patients who underwent allogeneic hematopoietic
                      stem cell transplantation in a real-world setting. We
                      reviewed 132 patients with AML who were treated with
                      intensive induction therapy and consecutive allogeneic stem
                      cell transplantation at our institution (42 FLT3-mutated AML
                      and 90 with FLT3 wildtype). We identified treatment with
                      midostaurin and/or FLT3i as an independent risk factor for
                      CAEs not resulting in higher non-relapse mortality (NRM) or
                      impaired overall survival (OS). Hence, close monitoring for
                      CAEs is warranted for these patients.},
      keywords     = {Acute myeloid leukemia (Other) / Allogeneic stem cell
                      transplantation (Other) / Cardiac toxicities (Other) /
                      Targeted FLT3 inhibitor therapy (Other)},
      cin          = {FM01},
      ddc          = {610},
      cid          = {I:(DE-He78)FM01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37552323},
      doi          = {10.1007/s00277-023-05396-y},
      url          = {https://inrepo02.dkfz.de/record/278358},
}